Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Siemens Sets A New Standard In Subtraction Angiography
The new application syngo iFlow from Siemens Healthcare makes it possible for the first time to
generic viagra online
Louisiana Cuts Rates For Medicaid Providers
"Louisiana will start paying less money Tuesday to many private health care providers for taking care of Medicaid patients, a move the state health department estimates will save $86 million this year," The Associated Press/The Advocate reports. Adults in the program may also have to pay a small co-pay if they visit emergency rooms for non-emergency care. "The cuts come as the health department shrinks its spending to $7.9 billion in the new fiscal year that began July 1, down $240 million from last year. Nearly all the cuts will be levied on the Medicaid program for the poor, elderly and disabled. But Jerry Phillips, state Medicaid director, said the department believes it can cover nearly two-thirds of that gap through efficiencies and the continuation of other cuts made during the last budget year."
News of the day
"Jumping Gene" Diminishes The Effect Of A New Type 2 Diabetes Risk Gene
Research led by the German Institute of Human Nutrition (DIfE) has identified a new gene associated with diabetes, together with a mechanism that makes obese mice less susceptible to diabetes. A genomic fragment that occurs naturally in some mouse strains diminishes the activity of the risk gene Zfp69. The researchers also found that the corresponding human gene (ZNF642) is especially active in overweight individuals with diabetes. The results of the study, which also involved scientists from the University of Leipzig and the German Cancer Research Center in Heidelberg, are published July 3 in the open-access journal PLoS Genetics.
Nutrition

AARP Biologics Study Based On Fuzzy Math, Flawed Assumptions

The following statement was issued by the Biotechnology Industry Organization (BIO) regarding a study on biosimilars presented to Congressional staff by the AARP: "The so-called AARP "study" is simplistic, misleading and extremely flawed. It is based on fuzzy math and even fuzzier assumptions. "The study cherry picks the best selling biologic products to draw erroneous conclusions, ignoring the bulk of the biologics market. The real facts show that only a small percentage of biotechnology products have the types of financial returns identified in the AARP study. If AARP had analyzed all of the more than 200 other FDA-approved biologics they conveniently left out of their fact sheet, their analysis would have reached a much different, and more credible, result. That"s because the "break even" point for all the other FDA-approved biologics approaches 50 years. "Greater than 90% of biologic products fail before even getting to clinical trials. Of those entering clinical trials, only 30% get approved by FDA. Of those approved products, only 34% generate profits equal to or greater than the development cost over the product"s lifecycle. "As one of the nation"s largest insurance providers, AARP has a lot to gain financially by using its considerable lobbying muscle to push Congress to pass biosimilars legislation that will benefit insurers by providing short-term cost savings at the risk of jeopardizing the continued development of advanced and breakthrough medicines and cures for patients. Biotechnology medicines extend and improve the quality of life - and provide renewed hope - for patients suffering from debilitating diseases such as cancer, HIV/AIDS, Parkinson"s, Multiple Sclerosis, diabetes and a host of rare diseases. "Congress should not develop public policy based on such a flawed and blatantly biased analysis. Now is the time to implement a pathway to biosimilars that safely increases access to the breakthrough therapies and cures for the patients of today, while preserving the incentives necessary to address the unmet medical needs of the patients of tomorrow." BIO


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009